Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Frequently asked questions
What sector does Brii Biosciences Limited (BRIBF) operate in?
Brii Biosciences Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Brii Biosciences Limited (BRIBF) current stock price?
As of the latest data, Brii Biosciences Limited stock price is $0.13, with a previous close of $0.13.
What is Brii Biosciences Limited (BRIBF) current market capitalization?
Brii Biosciences Limited market cap is approximately 93.86 million.
What is Brii Biosciences Limited (BRIBF) Earnings Per Share (EPS)?
The trailing EPS is -$0.04.
What is Brii Biosciences Limited (BRIBF) EBITDA?
Brii Biosciences Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -145.03 million.
Does Brii Biosciences Limited (BRIBF) pay dividends?
No. Brii Biosciences Limited does not pay a dividend.
What is Brii Biosciences Limited (BRIBF) beta (volatility) score?
Brii Biosciences Limited has a beta of 1.204, suggesting it is more volatile than the market.
